Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Maze Therapeutics (MAZE) Invested Capital (2024 - 2025)

Maze Therapeutics has reported Invested Capital over the past 2 years, most recently at $355.0 million for Q4 2025.

  • Quarterly Invested Capital rose 214.07% to $355.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $355.0 million through Dec 2025, up 214.07% year-over-year, with the annual reading at $355.0 million for FY2025, 214.07% up from the prior year.
  • Invested Capital was $355.0 million for Q4 2025 at Maze Therapeutics, down from $379.4 million in the prior quarter.
  • Over five years, Invested Capital peaked at $379.4 million in Q3 2025 and troughed at -$403.7 million in Q1 2024.